Serum-soluble IL-2 Receptor and IL-6 levels in patients with melanoma

Oncology (Switzerland)

Volumn 54, Issue 5, 1997, Pages 400-406

  Boyano, Maria Dolores ^a   Garcia Vazquez M D ^a   Gardeazabal, J ^b   De Galdeano, A García ^a   Smith Zubiaga, I ^a   Canavate M L ^a   Raton, J A ^b   Bilbao, I ^b   Diaz Perez J L ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Interleukin 6; Melanoma; Soluble interleukin 2 receptor; Tumor marker

Indexed keywords

INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SCHOOL CHILD; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; SKIN NEOPLASMS;

EID: 1842332652     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227726     Document Type: Article

References (41)

1. Parkinson DR, Abrams JS, Wiemik PH, Rayn-er AA, Margolin KA, Van Echo DA, Szntol M, Dutcher JP, Aronson FR, Doroshow JH, Atkins MB, Hawkins MJ: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990;8: 1650.
2. Fisher RI, Coltman CA Jr, Doroshow JH, Ravner AA, Hawkins MJ, Mier JW, Wiemik P, McMannis JD, Weiss GR, Margolin KA: Me-tastastic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: A phase II clinical trial. Ann Intern Med 1988:108:518.
3. García de Galdeano A, Boyano MD, Smilh-Zubiaga I, Cariavate ML: B16FI0 murine melanoma ceils express interleukin-2 and a functional interleukin-2 receptor. Tumor Biol 1996; 17:155.
4. Palomares T, Bilbao P, Alonso-Varona A, Bar-berà-Guillem E: The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16F10 melanoma. Cancer Immunol Immunother 1995:40:292-298.
5. Rimoldi D, Salvi S, Hartmann F. Schreyer M, Blum S, Zografos L, Plaisance S, Azzarone B, Carrel S: Expression of IL-2 receptors in human melanoma cells. Anticancer Res 1993:13: 555-564.
6. Alileche A, Plaisance S, Han DS, Rubinstein E, Mingari C, Bellomo R, Jasmin C, Azzarone B: Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene 1993;8: 1791-1796.
7. Plaisance S, Rubinstein A, Alileche A, Han DS, Sahraqui Y, Mingari MC, Bellomo R, Rimoldi D, Colombo MP, Jasmin C, Carrel S, Azzarone B: Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer 1993;55: 164-170.
8. Mallei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M: Expression of cytokine/ growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994;56:853-857.
9. Minami Y, Kono T, Miyazaki T, Taniguchi T: The IL-2 receptor complex: Its structure, function. and target genes. Annu Rev Immunol 1993:11:245-267.
10. Taniguchi T, Minami Y: The 1L-2/IL-2 receptor svstem: A current overview. Cell 1993;73: 5-8.
11. Rubin LA, Nelson DL: The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 1990:113:619-627.
12. Josimovic-Alasevic O, Herrman T, Diamant-stein T: Demonstration of two distinct formsof released Iow-affinity type interleukin 2 receptors. Eur J Immunol 1988:18:1855-1857.
13. Fcmandez-Botran R: Soluble cytokine receptors: Their role in immunoregulation. FASEB J 1991:5:2567-2574.
14. Oishi M, Johno M, Ono T, Honda M: Differences in 1L-2 receptor levels between mycosis fungoidcs and cutaneous type adult T-cell leukemia/lymphoma in the early stages of the disease. J Invest Dermatol 1994;102:710-715.
15. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, Kadin ME: Increased serum concentration of soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Arch Dermatol 1996;132:42-47.
16. Marcon L, Rubin LA, Kurman CC, Fritz ME, Longo DL, Uchiyama T, Edwards BK, Nelson DL: Elevated scrum levels of soluble Tac peptide in adult T-cell leukemia: Correlation with clinical status during chemotherapy. Ann Intern Med 1988:109:274-279.
17. Chilosi M, Semcnzato G, Vinante F, Menestri-na F, Zanotti R, Pizzolo G: Increased levels of soluble interleukin-2 receptor in non-Hodgkin’s lymphomas. AJPC 1989:92:186-191.
18. Rovelli F, Lissoni P, Crispino S, Bami S, Fu-magalli G, Paolorossi F, Tancini G: increased level of soluble intcrlcukin-2 receptor in advanced solid tumors: A preliminary study. Tu-mori 1988:74:633-637.
19. Pizzolo G, Chilosi M, Vinante F, Dazzi F, Les-tani M, Perona G, Benedetti F, Todcschini G, Vincenzi C, Trentin L, Semenzato G: Soluble interleukin 2 receptors in the scrum of patients with Hodgkin’s disease. Br J Cancer 1987:55: 427-428.
20. Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, Maluish AE: Serum soluble IL-2 receptor as a tumor marker in patients with hairy' cell leukemia. Blood 1988:5:1304- 1309.
21. Murakami S, Satomi A, Ishida K, Murai H, Malsuki M, Hiashimoto T: Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. Cancer 1994:74:2745-2748.
22. Piancatelli D, Pellegrini P, Berghella AM, Del Beato T, Calvisi G, Cori G, Adorno D, Cas-ciani CU: Detection of circulating ICAM-1 and soluble IL-2 receptor in serum of colorectal cancer patients. Int J Immunother 1994; 10:15-20.
23. Poulakis N, Sarandakou A, Rizos D, Phocas I, Kontozoglou Th, Polyzogopoulos D: Soluble interlcukin-2 receptor and other markers in primary lung cancer. Cancer 1991;68:1045-1049.
24. Fierro MT, Lisa F, Novelli M, Bertero M, Ber-nengo MG: Soluble interlcukin-2 receptor. CD4 and CD8 levels in melanoma: A longitudinal study. Clin Lab Invest 1992; 184:182- 189.
25. Tosato G, Pike S: Interferon 02/IL-6 is a costimulant for human T lymphocytes. J Immunol 1988:141:1556-1562.
26. Kuhweide R, Van Damme J, Ceuppens JL: TNF-alfa and interleukin 6 synergistically induce T cell growth. Eur J Immunol 1990:20: 1019-1025.
27. Houssiau F, C’oulie PG. Olive D, Van Snick J: Synergistic activation of human T cells by II.-1 and IL-6. Eur J Immunol 1988:18:653-656.
28. Luger TA, Krutmann J, Kirnbauer R, Urban-ski A, Schwartz T, Klappacher G, Kock A, Micksche K, Malejczyk J, Schaucr E, May LT, Sehgal PB: IFNJ2/IL-6 augments the activity of human natural killer cells. J Immunol 1989; 143:1206-1209.
29. Hiranc IS, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 1990:11:443-449.
30. Kishimoto T: The biology of interlcukin-6. Blood 1989;74:1-10.
31. Van Srick J: Interleukin-6: An overview. Annu Rev Immunol 1990;8:253-278.
32. Lu C, Kerbel RS: Intcrlcukin-6 undergoes transition from paracrine growth inhibitor to autocrine slimulator during human melanoma progression. J Cell Biol 1993; 120:1281-1288.
33. Lu C, Vickers MF, Kerbel RS: Interleukin 6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992:89:9215-9219.
34. Kerbel RS: Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 1992; 141:519-524.
35. Østenstad B: Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer. Acta Oncol 1992:31:413-415.
36. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble inlerleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172-3177.
37. Rubin LA, Gilbert J, Nelson DL: The released intcrleukin-2 receptor binds interlcukin-2 efficiently. J Immunol 1986;137:3841-3844.
38. Hirano T: Interleukin-6 and its relation to inflammation and disease. Clin Immunol Int-munopathol 1992;62:s60-s65.
39. Ershler WB, Sun WH. Binkley N, Gravenstein S, Volk MJ. Kamoske G, Klopp RG, Roecker EB, Daynes RA, Weindruch R: Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993:12: 225-230.
40. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY: Altered regulation of IL-6 production with normal aging. J Immunol 1993:150:5219-5230.
41. Blay JY, Négrier S, Combarct V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovchenko JF, Philip T, Favrot M: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992:52:3317-3322.